Burkina Faso vs Guatemala: Prevalence rate of hypertension in women aged 30-79
Burkina Faso
31.7
in 2019
Guatemala
32.6
in 2019
Burkina Faso rank
146th
Guatemala rank
144th
Prevalence rate of hypertension in women aged 30-79 over time
- Burkina Faso
- Guatemala
How they compare
Guatemala currently reports 32.6 against 31.7 in Burkina Faso, a difference of 0.9.
The two have swapped places 1 time across 30 shared years of data; in 1990 it was Burkina Faso ahead.
Burkina Faso ranks 146th and Guatemala ranks 144th of 195 countries.
Burkina Faso has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Burkina Faso | Guatemala | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 32.06 | 27.82 | 4.24 | Burkina Faso |
| 2000s | 32.92 | 29.18 | 3.74 | Burkina Faso |
| 2010s | 32.26 | 31.74 | 0.52 | Burkina Faso |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in women aged 30-79, Burkina Faso or Guatemala?
- Guatemala, at 32.6 against 31.7 in Burkina Faso as of 2019.
- What is the difference in prevalence rate of hypertension in women aged 30-79 between Burkina Faso and Guatemala?
- 0.9, with Guatemala ahead.
- How many years of comparable data are there for Burkina Faso and Guatemala?
- 30 years are reported by both, from 1990 to 2019.
- How do Burkina Faso and Guatemala rank globally for prevalence rate of hypertension in women aged 30-79?
- Burkina Faso ranks 146th and Guatemala ranks 144th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in women aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of female population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.